For a good wrapup of issues surrounding the New England Journal of Medicine article by Steven Nissen of the Cleveland Clinic showing that the heavily marketed diabetes drug Avandia from GlaxoSmithKline increases heart attack risk in the millions of patients who have taken it, go to GoozNews.com.
The Wall Street Journal headlined it "Sequel for Vioxx critic" - referring to Nissen who also raised some of the early red flag warnings about Vioxx.
Posted by schwitz at May 22, 2007 10:23 AM | TrackBack